TY - JOUR
T1 - The selenium-containing compound 3-((4-chlorophenyl)selanyl)-1-methyl-1H-indole reverses depressive-like behavior induced by acute restraint stress in mice
T2 - modulation of oxido-nitrosative stress and inflammatory pathway
AU - Casaril, Angela Maria
AU - Domingues, Micaela
AU - Bampi, Suely Ribeiro
AU - de Andrade Lourenço, Darling
AU - Padilha, Nathalia Batista
AU - Lenardão, Eder João
AU - Sonego, Mariana
AU - Seixas, Fabiana Kommling
AU - Collares, Tiago
AU - Nogueira, Cristina Wayne
AU - Dantzer, Robert
AU - Savegnago, Lucielli
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Rationale and objectives: Stress-induced alterations in oxidative and inflammatory parameters have been implicated in the pathophysiology of mood disorders. Based on the antioxidant and anti-inflammatory properties of the selenium-containing compound 3-((4-chlorophenyl)selanyl)-1-methyl-1H-indole (CMI), we assessed its ability to reverse depression-like behavioral alterations, neuroinflammation, and oxidative imbalance induced by acute restraint stress. Methods: Mice submitted to restraint for 240 min received CMI (1 or 10 mg/kg, orally) 10 min after the end of the stress induction. Behavioral and biochemical tests were carried out after further 30 min. Results: Restraint-induced depression-like behavior in the tail suspension test (TST), splash test, and new object exploration test was reversed by CMI. None of the treatments evoked locomotor alteration. In addition, CMI abrogated restraint-induced increases in plasma levels of corticosterone and in markers of oxidative stress and impaired superoxide dismutase and catalase activity in the prefrontal cortex (PFC) and hippocampus (HC). CMI also blocked stress-induced downregulation of mRNA levels of glucocorticoid receptor and brain-derived neurotrophic factor and upregulation of nuclear factor kappa B, inducible nitric oxide synthase, tumor necrosis alpha, indoelamine-2,3-dioxygenase, and glycogen synthase kinase 3 beta in PFC and HC. Conclusions: These preclinical results indicate that administration of selenium-containing compounds might help to treat depression associated with inflammation and oxidative stress. [Figure not available: see fulltext.].
AB - Rationale and objectives: Stress-induced alterations in oxidative and inflammatory parameters have been implicated in the pathophysiology of mood disorders. Based on the antioxidant and anti-inflammatory properties of the selenium-containing compound 3-((4-chlorophenyl)selanyl)-1-methyl-1H-indole (CMI), we assessed its ability to reverse depression-like behavioral alterations, neuroinflammation, and oxidative imbalance induced by acute restraint stress. Methods: Mice submitted to restraint for 240 min received CMI (1 or 10 mg/kg, orally) 10 min after the end of the stress induction. Behavioral and biochemical tests were carried out after further 30 min. Results: Restraint-induced depression-like behavior in the tail suspension test (TST), splash test, and new object exploration test was reversed by CMI. None of the treatments evoked locomotor alteration. In addition, CMI abrogated restraint-induced increases in plasma levels of corticosterone and in markers of oxidative stress and impaired superoxide dismutase and catalase activity in the prefrontal cortex (PFC) and hippocampus (HC). CMI also blocked stress-induced downregulation of mRNA levels of glucocorticoid receptor and brain-derived neurotrophic factor and upregulation of nuclear factor kappa B, inducible nitric oxide synthase, tumor necrosis alpha, indoelamine-2,3-dioxygenase, and glycogen synthase kinase 3 beta in PFC and HC. Conclusions: These preclinical results indicate that administration of selenium-containing compounds might help to treat depression associated with inflammation and oxidative stress. [Figure not available: see fulltext.].
KW - Acute restraint stress
KW - Antidepressant
KW - Neuroinflammation
KW - Oxidative stress
KW - Selenium
UR - http://www.scopus.com/inward/record.url?scp=85059669658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059669658&partnerID=8YFLogxK
U2 - 10.1007/s00213-018-5151-x
DO - 10.1007/s00213-018-5151-x
M3 - Article
C2 - 30610349
AN - SCOPUS:85059669658
SN - 0033-3158
VL - 236
SP - 2867
EP - 2880
JO - Psychopharmacology
JF - Psychopharmacology
IS - 10
ER -